Anti-inflammatory Effect of Batroxobin Combined With Anticoagulation in Patients With Cerebral Venous Thrombosis.
anti-inflammation
anticoagulation
batroxobin
cerebral venous thrombosis
platelet–lymphocyte ratio
systemic immune–inflammation index
Journal
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
ISSN: 1938-2723
Titre abrégé: Clin Appl Thromb Hemost
Pays: United States
ID NLM: 9508125
Informations de publication
Date de publication:
21 Jul 2024
21 Jul 2024
Historique:
medline:
21
7
2024
pubmed:
21
7
2024
entrez:
21
7
2024
Statut:
aheadofprint
Résumé
Inflammation is pivotal in the pathogenesis and development of cerebral venous thrombosis (CVT). Herein, we aimed to assess the anti-inflammatory effects of batroxobin combined with anticoagulation in CVT. Participants were categorized into the batroxobin group (batroxobin combined with anticoagulation) and the control group (anticoagulation only). Regression analysis was employed to explore the association between the number of episodes of batroxobin administration and the fluctuation of inflammatory indicators, as well as the proportion of patients with inflammatory indicators that were reduced after batroxobin use. Twenty-three cases (age: 39.9 ± 13.8 years, female: 39.1%) in the batroxobin group and 36 cases (40.3 ± 9.6 years, 52.8%) in the control group were analyzed. Compared to the control group, batroxobin combined with anticoagulation significantly decreased fibrinogen (
Identifiants
pubmed: 39033421
doi: 10.1177/10760296241264516
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10760296241264516Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.